Overview

• Market data show September sales of Rs 80 crore in India, up 42% from August and second only to Augmentin’s Rs 85 crore.
• Cumulative India revenue has reached about Rs 233 crore since launch, according to Pharmarack.
• The drug is available in 2.5 mg and 5 mg injections priced roughly Rs 14,000–17,500 per month, with many patients stepping up dose after four weeks.
• CDSCO cleared a ready‑to‑use KwikPen format, and trackers report Mounjaro vastly outpacing Novo Nordisk’s Wegovy in India, with over 96% share by volume.
• Wales’ 2025–2027 Healthy Weight plan creates a task group to examine NHS provision of tirzepatide, as prescribing remains limited to specialist services and some boards set higher BMI thresholds such as BCUHB’s >45.